DK1251850T3 - Anvendelse af et kombinationspræparat i cancerbehandling - Google Patents

Anvendelse af et kombinationspræparat i cancerbehandling

Info

Publication number
DK1251850T3
DK1251850T3 DK01908685T DK01908685T DK1251850T3 DK 1251850 T3 DK1251850 T3 DK 1251850T3 DK 01908685 T DK01908685 T DK 01908685T DK 01908685 T DK01908685 T DK 01908685T DK 1251850 T3 DK1251850 T3 DK 1251850T3
Authority
DK
Denmark
Prior art keywords
cancer treatment
combination preparation
irinotecan
temozolomide
cancer
Prior art date
Application number
DK01908685T
Other languages
Danish (da)
English (en)
Inventor
Peter J Houghton
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1251850T3 publication Critical patent/DK1251850T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01908685T 2000-01-26 2001-01-24 Anvendelse af et kombinationspræparat i cancerbehandling DK1251850T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17854100P 2000-01-26 2000-01-26

Publications (1)

Publication Number Publication Date
DK1251850T3 true DK1251850T3 (da) 2006-10-23

Family

ID=22652952

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01908685T DK1251850T3 (da) 2000-01-26 2001-01-24 Anvendelse af et kombinationspræparat i cancerbehandling

Country Status (13)

Country Link
US (1) US20030229112A1 (de)
EP (1) EP1251850B1 (de)
JP (1) JP2003521497A (de)
AT (1) ATE330600T1 (de)
AU (1) AU2001236529A1 (de)
CA (1) CA2397523A1 (de)
CY (1) CY1105564T1 (de)
DE (1) DE60120917T2 (de)
DK (1) DK1251850T3 (de)
ES (1) ES2263591T3 (de)
MX (1) MXPA02007242A (de)
PT (1) PT1251850E (de)
WO (1) WO2001054678A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454627A1 (en) * 2001-07-23 2003-02-20 Epidauros Biotechnologie Ag Methods for improved treatment of cancer with irinotecan based on mrp1
JP5208733B2 (ja) 2005-06-29 2013-06-12 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 組換えインターフェロンα２（ＩＦＮα２）変異体
US8258294B2 (en) * 2006-09-29 2012-09-04 Cipla Limited Process for the preparation of temozolomide and analogs
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
AR076784A1 (es) * 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
CN112263579A (zh) * 2020-11-10 2021-01-26 天津键凯科技有限公司 一种抗肿瘤药物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69616367T2 (de) * 1995-08-28 2002-06-27 Schering Corp., Kenilworth Kombinationstherapie für fortgeschrittenes krebsstadium mit temozolomid und cisplatin
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6346524B1 (en) * 1999-03-30 2002-02-12 Schering Corporation Cancer treatment with temozolomide

Also Published As

Publication number Publication date
CA2397523A1 (en) 2001-08-02
CY1105564T1 (el) 2010-07-28
DE60120917T2 (de) 2007-01-25
WO2001054678A3 (en) 2002-01-17
WO2001054678A2 (en) 2001-08-02
MXPA02007242A (es) 2002-12-09
AU2001236529A1 (en) 2001-08-07
EP1251850B1 (de) 2006-06-21
JP2003521497A (ja) 2003-07-15
EP1251850A2 (de) 2002-10-30
US20030229112A1 (en) 2003-12-11
ES2263591T3 (es) 2006-12-16
DE60120917D1 (de) 2006-08-03
ATE330600T1 (de) 2006-07-15
PT1251850E (pt) 2006-10-31

Similar Documents

Publication Publication Date Title
CY1107143T1 (el) Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
ATE302003T1 (de) Zubereitungen enthaltend apomorphin und sildenafil und ihre verwendung zur behandlung von erektiler dysfunktion
IL182352A (en) Use of et-743 in the preparation of a medicament for treating cancer and medical kits containing et-743
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
CY1107352T1 (el) Προεγχειρητικη θεραπευτικη αγωγη μετεγχειρητικου πονου
DK1677806T3 (da) Sammensætninger til behandling af akut og overbelastningsforårsaget forstuvning og forstrækning ved anvendelse af hyaluronsyre
DK0856312T3 (da) Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
ATE330600T1 (de) Kombinationspräparat zur krebstherapie
GB0020504D0 (en) Therapeutic method
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
EP1180380A3 (de) Katheteranordnung zur medizinischen Verwendung
BRPI0412408A (pt) métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
RU2002110165A (ru) Способ лечения хронических воспалительных заболеваний
PT1150981E (pt) Composto nucleosidico terapeutico
NO20043774L (no) The use of devazenide as analgesic agent
UA40393A (uk) Спосіб лікування хронічного обструктивного бронхіту
BRPI0407301A (pt) Uso de uma combinação, composição farmacêutica, kit, e, método para o tratamento de câncer em um animal de sangue quente tal como um ser humano
TNSN03022A1 (en) Method for treatment of inflammation
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
UA39087A (uk) Спосіб купірування абстинентного синдрому